Eugene Zvonkov/iStock via Getty Images Shares of Biodexa Pharmaceuticals ( NASDAQ: BDRX ) rallied 80% early Tuesday after the company reported positive Phase 2 data for its newly licensed drug eRapa in the treatment of familial adenomatous polyposis, or FAP. The study showed an overall non-progression rate of 83% at six months of treatment, with a 24% reduction in the total polyp burden compared with baseline. Two drug-related grade 3 serious adverse events were reported among the 30 participants, with 97% remaining on the treatment at six months, according to the company .
Biodexa plans to present the data at the Digestive Disease Week annual meeting, currently underway in Washington, D.C. The company plans to present polyp burden data at 12 months at the upcoming INSIGHT scientific conference, to be held in Barcelona from June 19 to 22.
Biodexa licensed eRapa, also known as rapamycin and sirolimus, from Emtora Biosciences in April. More on Biodexa Pharmaceuticals Biodexa shares rally 126% on rapamycin licensing deal Biodexa stock slides 7% amid data for two drug studies Seeking Alpha’s Quant Rating on Biodexa Pharmaceuticals Historical earnings data for Biodexa Pharmaceuticals Financial information for Biodexa Pharmaceuticals.
